LarryWonshinKwakMD

Deputy Director, Comprehensive Cancer Center Director, Toni Stephenson Lymphoma Center City of Hope

Dr. Kwak is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1987 - 1991
Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1984 - 1987
Northwestern University The Feinberg School of MedicineClass of 1982

PubMed

Journal Articles

Long‐Term Overall‐ and Progression‐Free Survival After Pentostatin, Cyclophosphamide and Rituximab Therapy for Indolent Non‐Hodgkin Lymphoma
Peter McLaughlin, M Alma Rodriguez, Sattva S Neelapu, Anas Younes, Lei Feng, Michelle A Fanale, Felipe Samaniego, Barbara Pro, Luis Fayad, Fredrick Hagemeister, Jorge ..., British Journal of Haematology
Phase I Study of an Active Immunotherapy for Asymptomatic Phase Lymphoplasmacytic Lymphoma with DNA Vaccines Encoding Antigen-Chemokine Fusion: Study Protocol
Sattva S Neelapu, D Lynne Smith, Vincent Y Lee, Larry W Kwak, Sheeba K Thomas, BioMed Central

Abstracts/Posters

Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in...
Larry W Kwak, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Overcoming CD19 Antigen Loss in B-Cell Malignancies with CAR T Cells Targeting BAFF-R
Larry W Kwak, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Preliminary Results from a Phase I Trial of Pembrolizumab Plus Vorinostat in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, a...
Larry W Kwak, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
PET-Adapted Nivolumab or Nivolumab Plus ICE As First Salvage Therapy in Relapsed or Refractory Hodgkin Lymphoma
Larry W Kwak, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

City of Hope Vaccine Experts Report Positive Results on Phase 1 Trial of Personalized Vaccine for Lymphoplasmacytic LymphomaSeptember 19th, 2024
New CAR T-cell Therapy for Blood Cancer Relapse Patients Could Be in Clinical Trials Within Six MonthsSeptember 25th, 2019
Researchers Say Second-Generation CAR T-cell Therapy Proves Successful in Early Studies, Human Trial PlannedSeptember 25th, 2019
Join now to see all

P1 - Combination Activated T-Cell And Vaccine Therapy In MyelomaNational Cancer Institute2010–2011
Career Development ProgramNational Cancer Institute2010–2011
Immunization Of Stem Cell Transplant Donors To Enhance Graft-Versus-Tumor EffectNational Cancer Institute2007–2008
Cellular And Humoral Immunity Against Myeloma IdiotypeDivision Of Clinical Sciences - Nci2004
Immunization Of Stem Cell Transplant Donors With MyelomaDivision Of Clinical Sciences - Nci2002–2004
Genetic Cancer VaccinesDivision Of Clinical Sciences - Nci2000–2004
Cancer Vaccines For LymphomasDivision Of Clinical Sciences - Nci2000–2004
Evaluation Of Cellular /Humoral Immunity Against MyelomaDivision Of Clinical Sciences - Nci2003
Evaluation Of Cellular And Humoral Immunity Against MyelDivision Of Clinical Sciences - Nci2001–2002
Immunization Of Stem Cell Transplant Donors With MyelomaDivision Of Clinical Sciences - Nci2000
Evaluation Of Cellular And Humoral Immunity Against Myeloma IdiotypeDivision Of Clinical Sciences - Nci2000
Idiotype Antigen Vaccine For Follicular LymphomasDivision Of Clinical Sciences - Nci1999
Evaluation Of Cellular And Humoral Immunity Against IdiotypeDivision Of Clinical Sciences - Nci1999